

## DAFTAR PUSTAKA

- Amirah N. 2010.” Karakteristik ibu penderita preeklampsia berat dan eklampsia serta hubungan dengan factor resiko di RSUP H. Adam Malik Medan. Fakultas Kedokteran Universtias Sumatera Barat.
- Aly AS, Khandelwal M, Zhao J, Mehmet AH, Sammel MD, Parry S. 2007. “ Neutrophils are stimulated by syncytiotrophoblast microvillous membranes to generate superoxide radicals in women with preeclampsia. *Am J Obstet Gyncol.* 190 (1): 252-8
- Bilano VL, Ota E, Ganchimeg T, Mori R, Souza JP. 2014. “ Risk factor of preeclampsia/eclampsia and its adverse outcome in low- and middle-income countries: A WHO secondary analysis. *Plos one* Vol 9. Issue 3. E91198.
- BPS, BKKBN, Kementerian Kesehatan & ICF International. 2013.“Indonesia Demographic and Health Survey 2012”. Jakarta: BPS, BKKBN, Kemenkes dan ICF International.
- Carty DM, Delles C, Dominiczak AF. 2008. “Novel Biomarkers for Predicting Preeclampsia”. *Trends Cardiovasc Med* 18 : 186-194.
- Chaiworapongsa T, Romero R, Korzeniewski SJ, Kusanovic JP, Soto E, Lam J, Dond Z, Than NG, Yeo L, et al. 2013. “ Pamertnal plasma concentrations of angiogenic/anti-angiogenic factors in the third trimester of pregnancy ti identify the patient at risk for stillbirth at or near term and severe late preeclampsia. *Am J Obstet Gynecol* : 208(4): 287.
- Centlow M, Carninci P, Nemeth K, Mezey E, Brownstein M, Hansson SR. 2008. “ Placental expression profiling in preeclampsia: local overproduction of hemoglobin may drive pathological changes. *Fertil Steril* : 90(5): 1834-1843.
- Cheng M, He P, Fu J. 2016. “ The relationship between circulating tissue transglutaminase, soluble fms-like tyrosine kinase-1, soluble endoglin and vascular endothelial growth factor in pre-eclampsia. *Journal of human hypertension* 30, 788-793.
- Dahlan, S. 2006. Besar Sampel dalam Penelitian Kedokteran Kesehatan Edisi 2. Jakarta: Arkans.
- Dulley L. 2009. The global Impact of Preeclampsia and Eclampsia. *Seminar in perinatologi.* 33:130-137.
- Eastabrook G, Hu Y, Dadelszen PV. 2008. The Role of Decidual Natural Killer Cells in Normal Placentation and in the Pathogenesis of Preeclampsia. *Journal Obstetric Gynecologic Clinical.* 30(6): 467-478.

- Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir GM, *et al.* 2008. "VEGF Inhibition and Renal Thrombotic Microangiopathy". *The New England journal of medicine.* 358: 1129-1136.
- Elhawary TM, El-Bendary AS, Demerdash H, 2012. Maternal Serum Endoglin as an Early Marker of Pre-eclampsia in High-Risk Patients. *International Journal of Womens Health.* 4: 521-525.
- Gaber K, Hamdy E, Hanafy A. 2009. "Soluble Endoglin as a New Marker for Prediction of Pre-eclampsia in Early Pregnancy". *Middle east fertility society* 15: 42-46.
- Hirashima C, Ahkuchi A, Matsubara S, Suzuki H, Takahashi K, Usui R, Suzuki M. 2008. "Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset". *Hipertens Res* Vol 31, No 8.
- Huppertz B. 2008. "Placental Origins of Preeclampsia: Challenging The Current Hypothesis". *American Heart Association. Hypertension.* 51 : 970-975.
- James JL, Chamley LW. 2005. "The Regulation of Trophoblast Differentiation By Oxygen in The First Trimester of Pregnancy". *Human Reproduction Update.* 12:137-144.
- Jasovic-Siveska E, Jasovic V, Stoilova S. 2011. "previous pregnancy history parity maternal age and risk of pregnancy induced hypertension". *Bratisl Lek Listy.* 112(4).
- Jeyabalan A. 2013. "Epidemiology of preeclampsia: impact of obesity". *Nutr Rev* : 71 (01).
- Khalil A, Syngelaki A, Maizi N, Zinevich N, Nicolaides KH. 2013. "Maternal age and adverse pregnancy outcome: a cohort study". *Ultrasound Obstet Gynecol* : 42: 634-643.
- Karashin E, Ceyhan ST, Goktolga U, Keskin U, Baser I. 2007. " Maternal Anemia and Perinatal Outcome. *Perinatal Journal* Vol 15.
- Keman K, Prasetyorini N, Langgar MJ. 2009. "Perbandingan Ekspresi p53, Bcl-2 dan Indeks Apoptosis Trofoblas Pada Preeklampsia/Eklampsia dan kehamilan Normal". *Majalah Obstetri Ginekologi Indonesia.*33-3: 151-159.
- Kullima AA, Kawuwa MB, Audu BM, Geidam AD, Mairiga AG. 2009. " Trend in maternal mortality in a tertiary institution in northern nigeria. *Annals of African Medicine.* Vol. 8, No. 4 : 2009:221-224.

- Lamminpaa R, Vehvilainen-Julkunen K, Gissler M, Heinonen S. 2012. “Preeclampsia complicated by advanced maternal age: a registry-based study on primiparous women in finland 1997-2008”. *BMC Pregnancy and childbirth* 12: 47.
- Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, *et al.* 2006. “Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia”. *New England Journal of Medicine* 355:992-1005.
- Liu Z, Afink GB, Dijke PT, 2012. “Soluble Fms-Like Tyrosine Kinase 1 and Soluble Endoglin are Elevated Circulating Anti-angiogenic Factors in Preeclampsia”. *Pregnancy hypertension : An International Journal of Womens Cardiovascular Health* 2: 358-367.
- Lopez-Novoa JM, Bernabeu C. 2012. *Atlas Genetics Cytogenetics Oncology Haematology*.
- Maharaj A.S.R, Walshe TE, Saint-Geniez MS, Venkatesha S, Maldonado AE, Himes NC, Matharu KS. 2008. “VEGF and TGF- $\beta$  are Required for The Maintenance of The Choroid Plexus and Ependyma. *Journal Exp Medical*. 205: 491-501.
- Marco GS, Reuter S, Hillebrand U, Amler S, Konig M, Larger E, Oberleithner H *et al.* 2009. “The Soluble Vegf Receptor Sflt-1 Cotributes To Endothelial Diysfunction In CKD”. *Journal of the American Society of Nephrology*.20: 2235-2245.
- Magee LA, Pels A, Helewa M, Rey E, Dadelszen PV. 2014. Diagnosis, Evaluation and Management of The Hipertensive Disorders of Pregnancy. *Pregnancy Hypertension: An International Journal of Women's Cardiovascular Helath*. 4: 105-145.
- Mihu D, Sabau L, Costin N, Ciortea R, Oancea M, Malutan A. 2010. “ Evaluation of leukocytes and Neutrophils, markers of inflammatory syndrome in preeclampsia”. *Applied medical infomatics* vol 27, No 3, pp: 15-23.
- Myers JE, Kenny LC, McCowan LME, Chan EHY, Dekker GA, Poston L, Simpson NAB, *et al.* 2013. Angiogenic Factors Combined With Clinical Risk Factors to Predict Preterm Pre-eclampsia in Nulliparous Women : a Predictive tets Accuracy Study. *BJOG*. 120: 1215-1223.
- Perucci LO, Gomes KB, Freitas LG, Godoi LC, Alpoim PN, Pinheiro MB, Miranda AS, *et al.* 2014. Soluble Endoglin, Transforming Growth Factor- $\beta$  1 and Soluble Tumor Necrosis Factor Alpha Receptors in Different Clinical Manifestations of Preeclampsia. *Plos ONE*.9(5):e97632.
- Powe CE, Levine RJ, Karumanchi SA. 2011. “Preeclampsia, A Disease of The Maternal Endothelium: The Role of Anti-Angiogenic Factors and

Implications for Later Cardiovascular Disease. *Howard Hughes Medical Institute*. 21:123 (24).

Raymon D, Peterson E.2011. “ A Critical Review of Early-Onset and Late-Onset Preeclampsia. *Obstetry Gynecol*.66(8): 497-506.

Reslan OM, Khalil RA, 2010. Molecular And Vascular Targets in The Pathogenesis and Management of The Hypertension Associated With Preeclampsia. *Cardiovascular Hematol Agents Med Chem*. 8(4): 204–226.

Rugolo L.M.S.S, Bentlin MR, Trindade CEP. 2011. “Preeclampsia : Effects of the Fetus and Newborn”. *American Academy of Pediatrics, Neonatal Reviews*. 12:e198.

Sanchez-Aranguren LC, Prada CE., Riano-Medina CE, Lopez M. 2014. “Endothelial Dysfunction and Preeclampsia” : Role Of Oxidative Stress. *Physiol* : 5:372.

Schutte JM, Steegers EAP, Schuitemaker NWE, Santema JG, de Boer K, Pel M, Vermeulen G, *et al*. 2009. Rise in Maternal Mortality in the Netherlands. *BJOG*. 117: 399-406.

Sezik M, Ozkaya O, Sezik HT, Yapar EG, Kaya H. 2006. “ Does marriage between first cousins have any predictive value for maternal and perinatal outcomes in pre-eclamsia. *J Obstet Gynaecol*. 32(5):475-81.

Sidani M, Siddik-Sayyid SM, 2011. Preeclampsia, A New Perspective In 2011. *M.E.J ANESTH*.21(2).

Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. 2010. Pre-eclampsia. *The Lancet*. 376, pp. 631-644.

Stephan H, Geipel A, Schwarz F, Kramer T, Wessel N, Faber R. 2008. “circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. *Am J Obstet Gynecol*. 198 (2):175.

Thomas CP, Andrews JI, Raikwar NS7, Kelley EA, Herse F, Dechend R, Golos TG, Liu KZ. 2009. “A Recently Evolved Novel Trophoblasts-Enriched Secreted Form of Fms-Like Tyrosine Kinase -1 Variants Is Up Regulated in Hypoxia And Preeclampsia”. *J Clin Endocrinol Metab*. 94 (7) : 2524-2530.

Vaiman D, Calicchio R, Miralles F. 2013. “Landscape of Transcriptional Deregulations In The Preeclamptic Placenta. *Plos One*. 8(6):e65498.

Valensise H, Vasapollo B, Gagliardi G, Novelli GP. 2008. Early and Late Preeclampsia: Two Different Maternal Hemodynamic States in The Latent Phase of The disease. *Hypertension*. 52 : 873-880.

Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim K, Yuan H, *et al.* 2006. "Soluble Endoglin Contributes to The Pathogenesis of Preeclampsia". *Natur Medicine*.12: 642-649.

Vinayagam V, Bobby Z, Habeebullah S, Latha CH, Bharadwaj S. 2017. Maternal and cord blood plasma sEng dan TGF- $\beta$ 1 in patients with hypertensive disorders of pregnancy: A pilot study in a south indian population. *Journal of clinical and diagnostic research* : vol 11(3): QC32-QC34.

WHO. (2014). Trends in Maternal Mortality 1990-2013 Estimates by WHO, UNICEF, UNFPA, The World Bank and The United Nations Population Division. Geneva: WHO, UNICEF, UNFPA, the World Bank, United Nation.

Wang A, Rana S, & Karumanchi S.A.S 2009. "Preeclampsia : The Role of Angiogenic Factors in Its Pathogenesis. *Physiology*. 24:147-158.

Winkstrom AK, 2007. "Biochemical and Epidemiological Studies of Early-Onset dan Late-Onset Preeclampsia". *Digital Comprehensif Summaries of Uppsala Dissertations From The Faculty of Medicine* 282.

Yusmardi. 2009. "Perbandingan kadar serum asam folat maternal penderita preeklamsi berat dengan kehamilan normal.

